Scholarlink

Background <p>Glioma is a highly prevalent malignant tumor of the central nervous system in children and is driven by complex genetic and environmental factors. <i>IGF2BP</i> family genes (<i>IGF2BP1</i>, <i>IGF2BP2</i>, and <i>IGF2BP3</i>) encode critical RNA epigenetic “readers” that participate in posttranscriptional gene regulation and modulate various cellular processes. However, the contributions of these gene variants to glioma risk remain unclear.</p> Methods <p>A multicenter case–control study was conducted, enrolling 360 patients with glioma and 547 cancer-free controls. Genotyping of 11 potentially functional polymorphisms within <i>IGF2BP</i> family genes was performed using the TaqMan assay. Unconditional logistic regression models were employed to estimate odds ratios and 95% confidence intervals. Furthermore, expression quantitative trait loci (eQTL) and The Cancer Genome Atlas (TCGA) clinical database analyses were conducted to investigate the potential regulatory mechanisms and clinical significance of the identified variants.</p> Results <p>We found that the <i>IGF2BP1</i> rs2270575 polymorphism was significantly associated with a decreased risk of glioma. Conversely, the <i>IGF2BP2</i> rs17289925 and rs7646419 polymorphisms were linked to increased glioma risk. Stratification and cumulative effect analyses revealed that harboring multiple risk genotypes of <i>IGF2BP1</i> or <i>IGF2BP2</i> substantially increased&#xa0;glioma susceptibility. This cumulative risk was especially notable among males, younger children (&lt; 60&#xa0;months), and patients diagnosed with early-stage (I + II) tumors. Additionally, eQTL and TCGA analyses revealed that the rs2270575 and rs7646419 alleles correlated significantly with altered mRNA expression levels of <i>CALCOCO2</i> and <i>AC099661.1</i> (<i>ENSG00000286086</i>), respectively, which further correlated with favorable molecular subtypes (<i>IDH</i> mutation status) and WHO tumor grades.</p> Conclusion <p>Genetic polymorphisms within <i>IGF2BP</i> family genes significantly modulate pediatric glioma susceptibility and have cumulative, subtype-specific, and age-dependent effects; thus, these genes may serve as promising noninvasive biomarkers for early risk stratification of childhood glioma.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Genetic variants in IGF2BP family genes are associated with glioma risk in Chinese children

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月16日

查看全文
  • Yuling Su,
  • Yuxiang Liao,
  • Li Yuan,
  • Linqian Wang,
  • Jiabin Liu,
  • Haixia Zhou,
  • Tianyou Wang,
  • Jing He

摘要

Background

Glioma is a highly prevalent malignant tumor of the central nervous system in children and is driven by complex genetic and environmental factors. IGF2BP family genes (IGF2BP1, IGF2BP2, and IGF2BP3) encode critical RNA epigenetic “readers” that participate in posttranscriptional gene regulation and modulate various cellular processes. However, the contributions of these gene variants to glioma risk remain unclear.

Methods

A multicenter case–control study was conducted, enrolling 360 patients with glioma and 547 cancer-free controls. Genotyping of 11 potentially functional polymorphisms within IGF2BP family genes was performed using the TaqMan assay. Unconditional logistic regression models were employed to estimate odds ratios and 95% confidence intervals. Furthermore, expression quantitative trait loci (eQTL) and The Cancer Genome Atlas (TCGA) clinical database analyses were conducted to investigate the potential regulatory mechanisms and clinical significance of the identified variants.

Results

We found that the IGF2BP1 rs2270575 polymorphism was significantly associated with a decreased risk of glioma. Conversely, the IGF2BP2 rs17289925 and rs7646419 polymorphisms were linked to increased glioma risk. Stratification and cumulative effect analyses revealed that harboring multiple risk genotypes of IGF2BP1 or IGF2BP2 substantially increased glioma susceptibility. This cumulative risk was especially notable among males, younger children (< 60 months), and patients diagnosed with early-stage (I + II) tumors. Additionally, eQTL and TCGA analyses revealed that the rs2270575 and rs7646419 alleles correlated significantly with altered mRNA expression levels of CALCOCO2 and AC099661.1 (ENSG00000286086), respectively, which further correlated with favorable molecular subtypes (IDH mutation status) and WHO tumor grades.

Conclusion

Genetic polymorphisms within IGF2BP family genes significantly modulate pediatric glioma susceptibility and have cumulative, subtype-specific, and age-dependent effects; thus, these genes may serve as promising noninvasive biomarkers for early risk stratification of childhood glioma.